Novel adjuvant teases T cells to respond to HCV Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response. more ➔
First drug found to reduce COVID-19-mortalityA clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients. more ➔
Germany puts €300m in CureVac AG for COVID-19 vaccineIn the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG. more ➔
Abbvie and Genmab team up in oncologyAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats. more ➔
Evox Therapeutics signs US$1.2bn deal with Eli LillyEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases. more ➔
Calliditas Therapeutics raise US$90m in Nasdaq IPOSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO. more ➔
Hyloris Pharmaceuticals prepared to go publicBelgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels. more ➔
NodThera bags US$55m in Series B roundNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement. more ➔
Bacterial colonisation differs by tumour typeAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities. more ➔
New algorithm predicts rheumatoid arthritisBased on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases. more ➔
